Ostarine and MK-2866 are names associated with enobosarm, a SARM studied for lean mass and physical function. Results in a particular study population are not a promise for every reader.
What did the human trial find?
A 2011 trial followed 120 older men and postmenopausal women for 12 weeks. It reported improved lean mass and some physical-function outcomes with treatment. That duration cannot establish long-term safety. Reference: Enobosarm phase II trial (2011)
Is lean mass entirely muscle?
Lean mass is a body-composition measurement. It should not be translated directly into pure muscle gain or an individual prediction. Examine measurement methods, the comparator and functional outcomes together.
What does selective mean?
Selectivity is a pharmacological concept, not a guarantee of no effects elsewhere. Hormonal and blood-test context matters, and research status is separate from medicine approval.
US FDA warns that SARMs are unapproved drugs and may cause serious health problems. FDA: SARMs
Frequently asked questions
How are Ostarine, MK-2866 and enobosarm related?
These names refer to the same research compound.
Can a 12-week trial answer long-term questions?
No. Longer follow-up and further adverse-effect data are needed.
How should this article be used?
Use it to identify the substance, understand what the cited research measured, and prepare questions for a qualified clinician. It is educational information, not an individual treatment plan.